- Home
- RBOT vs CLGN Comparison
RBOT vs CLGN Comparison
Compare RBOT & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- CLGN
- Stock Information
- Founded
- RBOT 2014
- CLGN 2004
- Country
- RBOT United States
- CLGN Israel
- Employees
- RBOT N/A
- CLGN N/A
- Industry
- RBOT Medical Specialities
- CLGN Industrial Specialties
- Sector
- RBOT Health Care
- CLGN Health Care
- Exchange
- RBOT Nasdaq
- CLGN Nasdaq
- Market Cap
- RBOT 33.9M
- CLGN 37.4M
- IPO Year
- RBOT N/A
- CLGN N/A
- Fundamental
- Price
- RBOT $5.39
- CLGN $2.42
- Analyst Decision
- RBOT Hold
- CLGN Strong Buy
- Analyst Count
- RBOT 2
- CLGN 2
- Target Price
- RBOT $9.25
- CLGN $12.50
- AVG Volume (30 Days)
- RBOT 20.7K
- CLGN 14.2K
- Earning Date
- RBOT 04-28-2025
- CLGN 05-28-2025
- Dividend Yield
- RBOT N/A
- CLGN N/A
- EPS Growth
- RBOT N/A
- CLGN N/A
- EPS
- RBOT N/A
- CLGN N/A
- Revenue
- RBOT N/A
- CLGN $515,000.00
- Revenue This Year
- RBOT N/A
- CLGN $2,177.67
- Revenue Next Year
- RBOT N/A
- CLGN $56.52
- P/E Ratio
- RBOT N/A
- CLGN N/A
- Revenue Growth
- RBOT N/A
- CLGN N/A
- 52 Week Low
- RBOT $4.27
- CLGN $2.20
- 52 Week High
- RBOT $19.00
- CLGN $6.75
- Technical
- Relative Strength Index (RSI)
- RBOT 33.03
- CLGN 28.88
- Support Level
- RBOT $5.07
- CLGN $2.31
- Resistance Level
- RBOT $5.95
- CLGN $2.49
- Average True Range (ATR)
- RBOT 0.57
- CLGN 0.14
- MACD
- RBOT 0.15
- CLGN 0.02
- Stochastic Oscillator
- RBOT 22.54
- CLGN 30.94
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.